Itamar Medical
Israeli medical-device company focused on diagnosing and managing sleep-disordered breathing, particularly obstructive sleep apnea.
Last updated October 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Itamar Medical is an Israeli medical-device company headquartered in Caesarea that develops, manufactures, and commercializes technologies for sleep-disordered breathing and cardiovascular assessment. Its best-known platform is WatchPAT, a home and ambulatory sleep-apnea diagnostic system based on Peripheral Arterial Tonometry, or PAT. The company also developed EndoPAT, a noninvasive device intended to assess endothelial function and support the early evaluation of vascular disease. The company was established in 1995 initially as a developer of technologies for assessing vascular abnormalities. Its early work produced EndoPAT and related vascular-assessment capabilities, while a second line of development addressed sleep disorders. Itamar Medical became associated with the proposition that sleep apnea should be identified and managed as a cardiovascular risk and comorbidity rather than treated only as a sleep complaint. This focus helped it build a position at the intersection of sleep medicine, cardiology, primary care, and remote or ambulatory diagnostics. WatchPAT is designed to collect physiological signals during sleep through a wrist-worn recorder and a finger-mounted sensor. Rather than reproducing every element of laboratory polysomnography, the system uses PAT-based vascular signals together with other recorded parameters and proprietary analysis to identify patterns associated with sleep apnea, respiratory events, oxygenation changes, and cardiovascular stress. The approach supports home-based testing and is intended to simplify access to diagnostic evaluation for patients and healthcare providers. Itamar also developed a broader care model linking diagnosis, clinical interpretation, and ongoing management of sleep apnea, with particular emphasis on cardiac patients. The company expanded internationally through regulatory clearances, distribution arrangements, technology integrations, and commercial partnerships. WatchPAT received U.S. Food and Drug Administration clearance for the U.S. market in 2002, and its indication was expanded in 2016 to include patients aged 12 and older. The company established or maintained operations and commercial relationships in the United States, Japan, the Netherlands, India, Russia, and other markets. It also pursued cloud-based workflow integration to improve coordination among sleep laboratories, physicians, and other care providers. Itamar Medical became publicly traded in 2007, with listings on the Tel Aviv Stock Exchange and Nasdaq. It raised additional capital during its period as an independent public company, including financing intended to support WatchPAT and EndoPAT commercialization and sales expansion. In 2021, ZOLL Medical Corporation acquired Itamar Medical, and the company’s stock was subsequently delisted. Under ZOLL ownership, Itamar Medical remains associated with sleep-apnea diagnosis and cardiovascularly oriented sleep-care technologies, with WatchPAT serving as its principal commercial platform.
History
Itamar Medical was founded in 1995 in Israel as a developer of medical technologies for assessing vascular defects and early cardiovascular disease. The company was named after Itamar Yaron, a founder’s brother who was killed during the Yom Kippur War while attempting to rescue an injured soldier and was later awarded a Medal of Courage. From its original vascular focus, the company developed two principal technology directions: EndoPAT for noninvasive assessment of endothelial function and WatchPAT for the diagnosis of sleep-disordered breathing. The company’s sleep business was built around Peripheral Arterial Tonometry, a method that detects changes in peripheral arterial vascular tone and related physiological responses during sleep. Itamar Medical used this approach to create a wearable alternative to some elements of conventional laboratory sleep testing. WatchPAT generally combines a wrist-worn recording unit with a finger sensor and software analysis. The company presented the technology as a way to make sleep-apnea assessment more accessible outside specialized sleep laboratories and to encourage physicians in cardiology and other fields to identify untreated sleep apnea. A significant early commercialization milestone came in 2002, when WatchPAT received U.S. FDA approval. In July of that year, Itamar Medical completed an $8 million financing round led by new investors including Bay City Capital. The proceeds were directed toward development and commercialization of WatchPAT and ETT PAT. The company continued international expansion and became publicly traded in 2007 on both the Tel Aviv Stock Exchange and Nasdaq. In 2011 it entered the Indian market, and in 2012 it established a Russian distribution relationship with Medical Diagnostic Methods. Itamar Medical also pursued partnerships intended to embed its products in broader clinical workflows. In 2013 it agreed to integrate WatchPAT with Somnoware Healthcare Systems’ cloud platform. In 2014 it entered a non-exclusive U.S. co-marketing agreement with Thorne Research covering EndoPAT and WatchPAT. These arrangements reflected the company’s effort to move beyond selling individual devices and toward a connected model for sleep-apnea diagnosis, interpretation, and care coordination. Regulatory expansion remained important. In July 2016, the FDA expanded WatchPAT’s indication to patients aged 12 and older, reducing the earlier minimum age of 17. In 2019, the company announced a private placement intended to raise nearly $12 million for sales and marketing of WatchPAT and EndoPAT. It also appointed cardiologist Jennifer Cook as Global Medical Director to guide clinical strategy, research, and scientific collaboration. In 2020, Itamar Medical raised $40 million on Nasdaq and received the National Sleep Foundation’s SleepTech Award. The company entered a further phase of expansion in 2021. It agreed to acquire Spry Health, whose FDA-cleared wrist-worn remote-monitoring system was viewed as complementary to Itamar’s interest in continuous monitoring and sleep-apnea care. Marga Ortigas-Wedekind also joined the board that year. In December 2021, ZOLL Medical Corporation acquired Itamar Medical. The transaction ended Itamar Medical’s independent public-company status and led to the delisting of its shares. Itamar Medical continues as a ZOLL-owned medical-device business associated primarily with WatchPAT, sleep-apnea diagnostics, and the cardiovascular implications of sleep-disordered breathing.
- 2021
ZOLL Medical completes acquisition
[1]Itamar Medical becomes part of ZOLL Medical Corporation and is subsequently delisted.
- 2016
WatchPAT indication expands to patients aged 12 and older
[1]The FDA lowers the minimum patient age for the device from 17 to 12.
- 2013
Somnoware cloud integration agreement
[1]WatchPAT is set to connect with Somnoware’s cloud platform to improve sleep-apnea workflow coordination.
- 2007
Public listings on Tel Aviv and Nasdaq exchanges
[1]Itamar Medical becomes a publicly traded company on the Tel Aviv Stock Exchange and Nasdaq.
- 2002
WatchPAT receives U.S. FDA approval
[1]U.S. regulatory clearance enables commercialization of WatchPAT in the American market.
- 1995
Itamar Medical is founded
[1]The company is established in Israel to develop technologies for vascular assessment and later expands into sleep-disorder diagnostics.
Products and positioning
A medical-technology specialist connecting convenient sleep-apnea diagnosis with cardiovascular risk assessment and longitudinal care. Its differentiation is centered on PAT-based, wearable, home-oriented testing and on encouraging cardiology and other non-sleep specialists to identify sleep apnea.
Sleep-apnea diagnostic system · 2002
WatchPAT
WatchPAT is Itamar Medical’s principal sleep-diagnostics platform. It is a wearable, home-oriented system that typically uses a wrist-worn recording unit and a finger-mounted sensor to capture physiological signals during sleep. Its Peripheral Arterial Tonometry technology evaluates vascular responses and related signals associated with respiratory disturbances, oxygenation changes, and cardiovascular workload. Proprietary algorithms analyze the recorded data and generate information used by clinicians in assessing sleep apnea. The device received U.S. FDA approval in 2002, and its indication was expanded in 2016 to include patients aged 12 and older.
Vascular and endothelial-function assessment device
EndoPAT
EndoPAT is a noninvasive vascular-assessment device developed from Itamar Medical’s original focus on early detection of cardiovascular disease. It uses peripheral arterial measurements to assess endothelial function and provide an indication of vascular health. The product was marketed alongside WatchPAT and was included in the company’s sales, marketing, and co-marketing activities. Its role within Itamar Medical’s portfolio reflects the company’s broader attempt to connect vascular biology, cardiovascular risk, and sleep-disordered breathing.
Peripheral arterial tonometry technology
ETT PAT
ETT PAT was among the technologies identified for development and commercialization in Itamar Medical’s 2002 financing announcement. The available reference material does not provide enough detail to describe its final commercial form, clinical indications, or current availability.
Brand decisions
2021
Acquire Spry HealthM&ABackground
Itamar Medical was seeking to advance continuous monitoring and broaden its capabilities in remote patient management related to sleep apnea.
Action taken
The company agreed to acquire Spry Health, including its FDA-cleared wrist-worn remote patient-monitoring system.
Aftermath
The transaction complemented Itamar Medical’s wearable diagnostic strategy. The available reference does not specify the final financial terms or subsequent product commercialization.
2021
Join ZOLL Medical CorporationM&ABackground
Itamar Medical had developed a specialized portfolio in sleep-apnea diagnosis and cardiovascularly oriented monitoring while operating as a public company.
Action taken
ZOLL Medical Corporation acquired Itamar Medical in December 2021.
Aftermath
Itamar Medical became ZOLL-owned and its stock was delisted, ending its independent public-company status.
2016
Expand WatchPAT’s FDA indication to younger patientsGeneration changeBackground
The company pursued broader access to WatchPAT for the assessment of sleep apnea in adolescents.
Action taken
The FDA expanded the indication to patients aged 12 and older, compared with the previous minimum age of 17.
Aftermath
The change widened the eligible patient population for WatchPAT in the United States.
2013
Integrate WatchPAT with Somnoware’s cloud platformStrategyBackground
Itamar Medical sought to improve coordination and delivery of sleep-apnea care by connecting its diagnostic device with a cloud-based clinical platform.
Action taken
The company entered an agreement with Somnoware Healthcare Systems to integrate WatchPAT with Somnoware’s software environment.
Aftermath
The agreement supported a more connected workflow for sleep testing and clinical management, although the available reference does not quantify its commercial effect.
Recent events
- 2021
Itamar Medical agrees to acquire Spry Health[1]
M&A · Product launch
The company agreed to acquire Spry Health and its FDA-cleared wrist-worn remote patient-monitoring system to advance continuous monitoring applications related to sleep apnea.
- 2021
Marga Ortigas-Wedekind joins the board[1]
Leadership change
Itamar Medical appointed Marga Ortigas-Wedekind to its board, adding experience in medical technology and digital health.
- 2021
ZOLL Medical acquires Itamar Medical[1]
M&A
ZOLL Medical Corporation acquired Itamar Medical, after which Itamar Medical’s public shares were delisted.
- 2020
Itamar Medical raises capital on Nasdaq[1]
Other
The company raised $40 million on Nasdaq during its final period as an independent public company.
- 2020
WatchPAT receives SleepTech Award[1]
Other
Itamar Medical received the SleepTech Award from the National Sleep Foundation in recognition of innovation in sleep technology.
- 2019
Itamar Medical announces private placement[1]
Other
The company announced a private placement expected to raise nearly $12 million, with proceeds directed toward sales and marketing for WatchPAT and EndoPAT.
- 2019
Jennifer Cook appointed Global Medical Director[1]
Leadership change
Cardiologist Jennifer Cook joined as Global Medical Director to lead research, clinical strategy, and scientific collaboration.
- 2016
FDA expands WatchPAT indication to adolescents[1]
Regulation · Product generation
The FDA expanded the WatchPAT indication to patients aged 12 and older, lowering the previous minimum age of 17.
- 2013
WatchPAT integrates with Somnoware’s cloud platform[1]
Other
Itamar Medical agreed to integrate WatchPAT with Somnoware Healthcare Systems’ cloud-based platform to support sleep-apnea workflow coordination.
- 2012
WatchPAT distribution agreement in Russia[1]
Other
Medical Diagnostic Methods began distributing WatchPAT in Russia under an arrangement with Itamar Medical.
Showing the 10 most recent.
Sources4 sources
- 1Itamar Medicalen.wikipedia.org
- 2Itamar Medical Appoints Scott P. Serota to its Board of Directorsbiospace.com
- 3Itamar Medical’s Sleep Apnea Device Wins US National Sleep Foundation Award - The Jewish Linkjewishlink.news
- 4Sleep diagnostics company Itamar Medical acquired by ZOLL Medical for $538 millioncalcalistech.com
Cite this profile: Cite the canonical profile. /brand-wiki/itamar-medical · Editorial policy · How profiles are compiled